ST
Therapeutic Areas
santen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| UPNEEQ® (oxymetazoline) Mini | Acquired Blepharoptosis | Marketed |
| Aflibercept biosimilar | Neovascular AMD, DME | Marketed |
| Verkazia® (Ciclosporin) | Severe Vernal Keratoconjunctivitis (VKC) | Marketed |
| DE-130 (EYP-1901) | Wet AMD | Phase 3 |
| DE-126 (KSI-501) | DME, RVO | Phase 2 |
| DE-127 | Ocular Inflammatory Diseases | Phase 2 |
| SNT-5505 | Glaucoma / OHT | Phase 2 |